7,614 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,614 shares of the medical equipment provider's stock, valued at approximately $549,000.

Other institutional investors have also added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. boosted its holdings in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider's stock valued at $3,967,000 after acquiring an additional 130 shares during the last quarter. Covestor Ltd raised its position in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock valued at $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares during the period. Finally, Empirical Finance LLC grew its holdings in shares of Hologic by 1.8% during the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider's stock worth $690,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

HOLX stock traded up $0.12 during trading on Thursday, hitting $64.32. The company had a trading volume of 1,953,696 shares, compared to its average volume of 2,481,109. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $14.43 billion, a price-to-earnings ratio of 20.29, a P/E/G ratio of 2.12 and a beta of 0.97. The business has a 50 day moving average of $70.09 and a 200 day moving average of $76.74. Hologic, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HOLX. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.